H[2] blockers and alcohol
This article was originally published in The Tan Sheet
Executive Summary
H[2] blockers' effect on alcohol blood levels is called a "nonproblem" by Michael Levitt, MD, V-A Medical Center, Minneapolis, in an editorial in the April 1 Annals of Internal Medicine. Levitt's editorial accompanies a study by Jean-Pierre Raufman, et al., SUNY-Health Science Center, Brooklyn, that found that SmithKline Beecham's Tagamet (cimetidine), Merck's Pepcid (famotidine), Lilly's Axid (nizatidine), and Glaxo's Zantac (ranitidine) "do not alter serum ethanol levels" of "healthy nonalcoholic men" following "moderate alcohol consumption after an evening meal." The Raufman study was one of several reviewed by an FDA advisory committee March 12 that decided that H[2] blockers' effect on blood alcohol is not "clinically significant" ("The Tan Sheet" March 22, p. 4).
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning